31-10-2024 |
PM |
|
REGN |
Regeneron Pharmaceuticals, Inc. |
102,220 |
11.73 |
10.06 |
10.17 |
Regeneron Pharmaceuticals Non-GAAP EPS of $12.46 beats by $0.75, revenue of $3.72B beats by $50M [10/31/2024 6:31 AM] |
838.22 |
-84.57 (-9.16%) |
875.02 |
-47.77 (-5.18%) |
772.84 - 1,211.20 |
1,907,582 |
770,000 |
12,630 |
|
|
01-08-2024 |
PM |
|
REGN |
Regeneron Pharmaceuticals, Inc. |
118,760 |
10.10 |
8.91 |
8.79 |
Regeneron Pharmaceuticals Non-GAAP EPS of $11.56 beats by $0.94, revenue of $3.55B beats by $160M [8/1/2024 6:32 AM] |
1,094.50 |
15.31 (1.42%) |
1,070.00 |
-9.19 (-0.85%) |
726.11 - 1,106.16 |
717,202 |
400,000 |
2,344 |
|
|
02-05-2024 |
PM |
|
REGN |
Regeneron Pharmaceuticals, Inc. |
97,960 |
7.97 |
8.46 |
8.44 |
Regeneron Pharmaceuticals misses top-line and bottom-line estimates; updates FY24 outlook [5/2/2024 6:32 AM] |
936.29 |
32.81 (3.63%) |
895.00 |
-8.48 (-0.94%) |
684.80 - 998.33 |
913,580 |
470,000 |
4,449 |
|
|
02-02-2024 |
PM |
|
REGN |
Regeneron Pharmaceuticals, Inc. |
102,710 |
10.18 |
9.10 |
10.96 |
Regeneron Pharmaceuticals beats top-line and bottom-line estimates; initiates FY24 outlook [2/2/2024 6:32 AM] |
944.76 |
-13.02 (-1.36%) |
971.00 |
13.22 (1.38%) |
684.80 - 973.99 |
619,525 |
510,000 |
2,417 |
|
|
02-11-2023 |
PM |
|
REGN |
Regeneron Pharmaceuticals, Inc. |
84,660 |
10.17 |
9.39 |
9.98 |
Regeneron Pharmaceuticals beats Q3 top and bottom line estimates; updates FY23 outlook [11/2/2023 6:32 AM] |
818.79 |
27.52 (3.48%) |
818.79 |
0.0 (0.00%) |
668.00 - 853.97 |
697,326 |
440,000 |
21,907 |
|
|
03-08-2023 |
PM |
|
REGN |
Regeneron Pharmaceuticals, Inc. |
81,080 |
8.79 |
8.48 |
9.77 |
Regeneron Pharmaceuticals Non-GAAP EPS of $10.24 beats by $0.34, revenue of $3.16B beats by $140M [8/3/2023 6:31 AM] |
771.45 |
39.33 (5.37%) |
771.45 |
0.0 (0.00%) |
572.22 - 837.55 |
1,019,923 |
690,000 |
7,313 |
|
|
04-05-2023 |
PM |
6:30 AM ET (May 4) |
REGN |
Regeneron Pharmaceuticals, Inc. |
87,600 |
8.44 |
7.71 |
11.49 |
Regeneron Pharmaceuticals Non-GAAP EPS of $10.09 beats by $0.53, revenue of $3.16B beats by $160M [5/4/2023 6:32 AM] |
754.56 |
-48.61 (-6.05%) |
772.05 |
-31.12 (-3.87%) |
538.01 - 837.55 |
1,083,477 |
540,000 |
12,165 |
|
|
03-02-2023 |
PM |
6:30 AM ET (Feb 3) |
REGN |
Regeneron Pharmaceuticals, Inc. |
82,550 |
10.96 |
8.18 |
23.72 |
Regeneron Pharmaceuticals reports Q4 earnings beat; initiates FY23 guidance [2/3/2023 6:34 AM] |
784.13 |
32.93 (4.38%) |
765.43 |
14.23 (1.89%) |
538.01 - 789.95 |
1,188,161 |
620,000 |
2,129 |
|
|
03-11-2022 |
PM |
6:30 AM ET (Nov 3) |
REGN |
Regeneron Pharmaceuticals, Inc. |
82,840 |
9.98 |
8.55 |
15.37 |
Regeneron Pharmaceuticals Non-GAAP EPS of $11.14 beats by $1.52, revenue of $2.94B beats by $80M [11/3/2022 6:31 AM] |
739.68 |
-0.80 (-0.11%) |
734.00 |
-6.48 (-0.88%) |
538.01 - 764.59 |
627,643 |
710,000 |
703 |
|
|
03-08-2022 |
PM |
6:30 AM ET (Aug 3) |
REGN |
Regeneron Pharmaceuticals, Inc. |
64,380 |
9.77 |
8.53 |
27.97 |
Regeneron Pharmaceuticals Non-GAAP EPS of $9.77 beats by $1.02, revenue of $2.86B beats by $60M [8/3/2022 6:34 AM] |
608.64 |
33.68 (5.86%) |
589.00 |
14.04 (2.44%) |
538.01 - 747.42 |
853,979 |
540,000 |
108,898 |
|
|
04-05-2022 |
PM |
6:30 AM ET (May 4) |
REGN |
Regeneron Pharmaceuticals |
71,539 |
11.49 |
9.37 |
0.00 |
Regeneron Pharmaceuticals Non-GAAP EPS of $11.49 beats by $1.69, revenue of $2.97B beats by $280M [5/4/2022 6:33 AM] |
660.49 |
0.0 (0.00%) |
675.00 |
14.51 (2.20%) |
478.40 - 747.42 |
796,036 |
550,000 |
8,377 |
|
|
04-02-2022 |
PM |
6:30 AM ET (Feb 4) |
REGN |
Regeneron Pharmaceuticals, Inc. |
66,980 |
23.72 |
18.49 |
8.72 |
Regeneron Pharmaceuticals Non-GAAP EPS of $23.72 beats by $3.67, revenue of $4.95B beats by $460M [2/4/2022 6:31 AM] |
623.43 |
2.74 (0.44%) |
615.00 |
-5.69 (-0.92%) |
441.00 - 686.62 |
1,077,374 |
930,000 |
9,669 |
|
-
Can Regeneron Pharma top Q4 earnings forecast amid COVID challenges? [2/3/2022 9:12 AM]
-
Regeneron Pharmaceuticals Non-GAAP EPS of $23.72 beats by $3.67, revenue of $4.95B beats by $460M [2/4/2022 6:31 AM]
-
Regeneron more than doubles Q4 revenue powered by sales for COVID-19 antibody [2/4/2022 8:03 AM]
-
10 Biotech Stocks to Buy According to Matthew Strobecks Birchview Capital [Feb-03-22 02:36PM]
-
Appleton Partners Inc Buys Alexandria Real Estate Equities Inc, Global X The Global X Video ... [Feb-03-22 01:38PM]
-
Pacer Advisors, Inc. Buys LyondellBasell Industries NV, CVS Health Corp, Dow Inc, Sells , ... [Feb-03-22 01:38PM]
-
Why Regeneron (REGN) Might Surprise This Earnings Season [Feb-03-22 08:32AM]
-
Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results [Feb-04-22 06:30AM]
-
Regeneron shares up premarket after Q4 revenue doubles and blows past estimates [Feb-04-22 06:41AM]
-
Dow Jones Futures Fall Ahead Of Jobs Report; Amazon Soars, But Ford Dives On Earnings [Feb-04-22 08:08AM]
-
Dow Jones Futures Slide As Yields Surge On Jobs Report; Amazon Soars, But Ford Dives On Earnings [Feb-04-22 08:37AM]
-
Regeneron Stock Fell Despite Strong Earnings. This Is Why. [Feb-04-22 09:18AM]
-
Regeneron Scores Quarterly Beat On Covid Cocktail But Future Sales Are Shaky [Feb-04-22 09:16AM]
-
Dow Jones Falls As Yields Surge On Jobs Report; Amazon Soars, But Ford Dives On Earnings [Feb-04-22 09:32AM]
-
Regeneron (REGN) Q4 Earnings and Revenues Top Estimates [Feb-04-22 08:05AM]
-
Four drug makers raked in $14 billion in sales of COVID-19 treatments in 2021. How will they do this year? [Feb-04-22 10:12AM]
-
This Will Put a Big Dent in Eli Lilly's and Regeneron's Sales This Year [Feb-04-22 11:00AM]
-
Regeneron's Q4 Sales, Profits More Than Double With Boost From COVID-19 Treatment Sales [Feb-04-22 08:01AM]
-
Sanofi CFO details earnings, COVID-19 vaccine outlook, and drug development [Feb-04-22 11:46AM]
-
Regeneron (REGN) Beats on Q4 Earnings, Gains on REGEN-COV [Feb-04-22 10:20AM]
-
Sanofi (SNY) Q4 Earnings Beat, Vaccines Hurt Sales Growth [Feb-04-22 10:03AM]
-
Regeneron Scores Quarterly Beat But How Long Will Its Covid Tailwind Persist? [Feb-04-22 12:22PM]
-
Stocks Drop as Jobs Report Increases Rate-Hike Jitters [Feb-04-22 12:05PM]
-
Kodiak (KOD) Completes Enrolling Patients in Retina-Based Studies [Feb-04-22 11:55AM]
-
Cowa, Llc Buys Avantis U.S. Small Cap Value ETF, Dimensional International Core Equity Market ... [Feb-04-22 05:38PM]
|
04-11-2021 |
PM |
6:30 AM ET (Nov 4) |
REGN |
Regeneron Pharmaceuticals, Inc. |
68,360 |
15.37 |
9.81 |
7.68 |
Regeneron Pharmaceuticals EPS beats by $5.43, beats on revenue [11/4/2021 6:33 AM] |
647.63 |
-4.47 (-0.69%) |
647.63 |
0.0 (0.00%) |
441.00 - 686.62 |
1,451,350 |
770,000 |
10,704 |
|
|
05-08-2021 |
PM |
6:30 AM ET (Aug 5) |
REGN |
Regeneron Pharmaceuticals, Inc. |
62,490 |
27.97 |
9.12 |
6.29 |
Regeneron Pharmaceuticals EPS beats by $8.09, beats on revenue [8/5/2021 6:33 AM] |
602.33 |
21.38 (3.68%) |
587.00 |
6.05 (1.04%) |
441.00 - 660.00 |
1,501,260 |
550,000 |
22,300 |
|
|
06-05-2021 |
PM |
6:30 AM ET (May 6) |
REGN |
Regeneron Pharmaceuticals, Inc. |
51,680 |
10.09 |
7.78 |
5.87 |
Regeneron Pharmaceuticals EPS beats by $1.19, misses on revenue [5/6/2021 6:31 AM] |
498.68 |
16.26 (3.37%) |
498.68 |
0.0 (0.00%) |
441.00 - 664.64 |
1,525,703 |
740,000 |
6,225 |
|
|
05-02-2021 |
PM |
6:30 AM ET (Feb 5) |
REGN |
Regeneron Pharmaceuticals, Inc. |
53,350 |
8.72 |
7.11 |
6.58 |
Regeneron Pharmaceuticals EPS beats by $1.24, beats on revenue [2/5/2021 6:32 AM] |
498.63 |
-0.21 (-0.04%) |
513.48 |
14.64 (2.93%) |
363.00 - 664.64 |
1,425,903 |
1,037,122 |
61,263 |
|
|
05-11-2020 |
PM |
6:30 AM ET (Nov 5) |
REGN |
Regeneron Pharmaceuticals, Inc. |
59,280 |
7.68 |
9.52 |
5.84 |
Regeneron Pharmaceuticals EPS beats by $1.37, beats on revenue [11/5/2020 6:32 AM] |
588.81 |
1.67 (0.28%) |
588.81 |
0.0 (0.00%) |
322.11 - 664.64 |
900,627 |
727,996 |
16,939 |
|
|
05-08-2020 |
PM |
6:30 AM ET (Aug 5) |
REGN |
Regeneron Pharmaceuticals, Inc. |
64,850 |
6.29 |
5.59 |
5.29 |
Regeneron Pharmaceuticals EPS beats by $1.20, beats on revenue [8/5/2020 6:32 AM] |
636.32 |
-12.11 (-1.87%) |
655.00 |
6.57 (1.01%) |
271.37 - 664.64 |
498,556 |
646,962 |
11,776 |
|
|
05-05-2020 |
PM |
6:30 AM ET (May 5) |
REGN |
Regeneron Pharmaceuticals, Inc. |
59,130 |
5.87 |
4.89 |
3.75 |
Regeneron Pharmaceuticals EPS beats by $0.51, beats on revenue [5/5/2020 6:32 AM] |
573.22 |
31.40 (5.80%) |
563.00 |
21.18 (3.91%) |
271.37 - 581.00 |
686,644 |
963,756 |
20,664 |
|
|